Adds to existing law to establish provisions regarding breast cancer screening.
House Bill 134 creates a new chapter in Title 39, Idaho Code, to require certain health benefit plans to cover annual supplemental breast cancer screening for people who are at increased risk. The bill defines “supplemental breast screening” to include medically necessary and clinically appropriate MRI, abbreviated MRI, contrast mammography, or ultrasound when MRI or other imaging is not possible, if recommended by the treating physician and no abnormality is already suspected.
The coverage mandate applies to a broad range of health benefit plans, including individual and group insurance policies, hospital service contracts, managed care plans, fraternal benefit societies, and exchange plans. For eligible individuals, the required minimum coverage includes all costs associated with one supplemental screening each year when risk factors are present, such as a personal or family history of breast cancer, atypical breast histology, genetic predisposition, prior thoracic radiation, a calculated lifetime risk above 20 percent, extremely dense breasts, or heterogeneously dense breasts combined with certain genetic or syndrome-related risk factors. The bill allows deductibles, copayments, and coinsurance to continue to apply to breast imaging beyond the minimum coverage required.
This bill would add a new insurance coverage requirement in Idaho law, expanding mandated benefits for breast cancer screening under Title 39. It would affect insurers and other health benefit plan issuers by requiring annual supplemental screening coverage for defined high-risk populations, potentially increasing plan costs while improving access to earlier detection services. The act is set to take effect January 1, 2026, despite the emergency clause.
The voting history suggests the bill was generally well received, passing the House 62-6 and the Senate 25-10. That margin indicates broad bipartisan support for expanding breast cancer screening coverage, with only a relatively small minority opposed. No committee transcript was provided, so the available record shows strong overall legislative approval but does not reveal detailed floor debate or committee concerns.
The main likely point of contention is the insurance mandate itself: requiring plans to pay for supplemental imaging for defined high-risk patients may raise premium or utilization concerns for insurers and cost-sensitive lawmakers. Another possible issue is the breadth and technical detail of the risk-based eligibility criteria, including dense breast tissue categories, genetic mutations, and syndrome-based risk factors, which could affect how claims are administered and when coverage is triggered. The recorded opposition in both chambers suggests some lawmakers were uneasy with the mandate or its fiscal implications, but the bill still advanced with substantial support.